Výsledky vyhledávání

Editorial & Opinion

Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance.

Autor: Chen S; Health Analytics, Lane Clark & Peacock LLP, London, England, UK., Tikhonovsky N; Health Analytics, Lane Clark & Peacock LLP, London, England, UK., Dhanji N; Health Analytics, Lane Clark & Peacock LLP, London, England, UK., Ramagopalan S; Health Analytics, Lane Clark & Peacock LLP, London, England, UK; Centre for Pharmaceutical Medicine Research, King's College London, England, UK. Electronic address: sreeram.ramagopalan@lcp.uk.com.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Feb; Vol. 27 (2), pp. 265-267. Date of Electronic Publication: 2023 Dec 21.

Zobrazit plný text záznamu

Akademický článek

P52 Incorporating Equity Into UK Decision-Making: The Need for Better Equity Data for Distributional Cost-Effectiveness Analysis.

Autor: Dhanji, N¹ (AUTHOR), Edwards, H² (AUTHOR), Kettle, J¹ (AUTHOR), Treharne, C¹ (AUTHOR), Ramagopalan, S¹ (AUTHOR), Clifton-Brown, E.³ (AUTHOR), Pearson-Stuttard, J.¹ (AUTHOR)

Publikováno v: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS12-S13. 2p.

Zobrazit plný text záznamu

Akademický článek

HTA305 Development of a Stepwise Approach to Assessing the Feasibility of Conducting a Distributional Cost-Effectiveness Analysis.

Autor: Dhanji, N¹ (AUTHOR), Treharne, C¹ (AUTHOR), Pearson-Stuttard, J.¹ (AUTHOR), Ramagopalan, S¹ (AUTHOR)

Publikováno v: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS414-S415. 2p.

Zobrazit plný text záznamu

Akademický článek

SA22 Mapping the Landscape of Distributional Cost-Effectiveness Analysis: A Systematic Review of Applications and Methodological Considerations.

Autor: Venkatesh, S.¹ (AUTHOR), Dhanji, N.¹ (AUTHOR), Treharne, C.¹ (AUTHOR), Pearson-Stuttard, J.¹ (AUTHOR), Ramagopalan, S.¹ (AUTHOR)

Publikováno v: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS617-S617. 1p.

Zobrazit plný text záznamu

Akademický článek

EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia

Autor: Dhanji, N., Van De Wetering, G., Guiot, V., Barco, V., Mejia, A., May, J.R., Garcia, J., Dyer, M.

Publikováno v: In Value in Health June 2023 26(6) Supplement:S74-S74

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.

Autor: Dhanji N; Modeling & Meta-Analysis, OPEN Health, Oxford, UK., Decimoni TC; Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazil., Dyer MTD; WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK., May JR; WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK., van de Wetering G; Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlands., Petersohn S; Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlands., Nickel K; Modeling & Meta-Analysis, OPEN Health, Berlin, Germany., Silva A; Commercialization Intercon Medical, Medical and Regulatory Affairs, São Paulo, SP, Brazil., Muniz DQB; Hospital Sírio-Libanês, São Paulo, Brazil., Casagrande D Oliveira AP; Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazil.

Publikováno v: Journal of medical economics [J Med Econ] 2023 Jan-Dec; Vol. 26 (1), pp. 1108-1121.

Zobrazit plný text záznamu

Akademický článek

Patient and Public Involvement (PPI) in Health Economics Methodology Research: Reflections and Recommendations.

Autor: Al-Janabi H; University of Birmingham, Birmingham, UK. h.aljanabi@bham.ac.uk., Coles J; Lived Experience Advisory Panel, University of Birmingham, Birmingham, UK., Copping J; Lived Experience Advisory Panel, University of Birmingham, Birmingham, UK., Dhanji N; University of Birmingham, Birmingham, UK., McLoughlin C; University of Birmingham, Birmingham, UK., Murphy J; Lived Experience Advisory Panel, University of Birmingham, Birmingham, UK., Nicholls J; Lived Experience Advisory Panel, University of Birmingham, Birmingham, UK.

Publikováno v: The patient [Patient] 2021 Jul; Vol. 14 (4), pp. 421-427.

Zobrazit plný text záznamu

Akademický článek

POSA150 Cost-Effectiveness Analysis of First-Line (1L) Systemic Treatments in Advanced Renal Cell Carcinoma (aRCC) in France

Autor: Tempelaar, S, Kroep, S, Marie, L, Juban, L, Kurt, M, Ejzykowicz, F, May, JR, Gaudin, AF, Dhanji, N, Branchoux, S

Publikováno v: In Value in Health January 2022 25(1) Supplement:S63-S63

Zobrazit plný text záznamu

Akademický článek

Estimating an exchange-rate between care-related and health-related quality of life outcomes for economic evaluation: An application of the wellbeing valuation method.

Autor: Dhanji N; Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Brouwer W; Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, Netherlands., Donaldson C; Yunus Centre for Social Business, Glasgow Caledonian University, Glasgow, UK., Wittenberg E; Center for Health Decision Science, Harvard University, Boston, Massachusetts, USA., Al-Janabi H; Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Publikováno v: Health economics [Health Econ] 2021 Nov; Vol. 30 (11), pp. 2847-2857. Date of Electronic Publication: 2021 Aug 28.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání